Vaccine panel's hepatitis B vote signals further turbulence for immunization policy, public trust

TL;DR

The CDC's Advisory Committee on Immunization Practices (ACIP) voted to change the universal recommendation for the newborn hepatitis B vaccine dose.
The new policy reserves the birth dose for infants born to mothers who test positive for hepatitis B, with others having the option to delay until 2 months.
Critics argue this change, influenced by individuals with anti-vaccine ties, could reverse decades of progress in preventing hepatitis B infections, which can lead to liver cancer and death.
Hepatitis B can spread through ordinary family contact and household surfaces, making universal vaccination crucial.
Past risk-based vaccination strategies for hepatitis B failed to contain transmission effectively.
The universal birth dose, implemented in 1991, has led to a greater than 99% drop in pediatric hepatitis B infections in the U.S.
Concerns exist that the shift to parental choice may disproportionately affect vulnerable populations and that testing alone cannot guarantee protection due to potential false negatives and logistical failures.
The United States is now the only country to abandon a universal hepatitis B birth dose recommendation.

Continue reading the original article